Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ISM6331 in Advanced/Metastatic Mesothelioma or Other Advanced Solid Tumors
NCT06566079Phase 2Recruiting
- Sponsor
- Insilico Medicine
- Start
- Dec 2024
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of ISM6331 in malignant mesothelioma, solid tumor, sponsored by Insilico Medicine. Started Dec 2024; status: recruiting.
02
Drugs
ISM6331
03
Conditions
malignant mesotheliomasolid tumor
Beyond the preview
Go deeper on NCT06566079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06566079.